Breast Cancer
R E S E A R C H

Open Access

CrossMark

Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence

Joseph A Caruso[1,5,7], Cansu Karakas[1,2], Jing Zhang[2], Min Yi[3], Constance Albarracin[2], Aysegul Sahin[2], Melissa Bondy[4], Jinsong Liu[2,5], Kelly K. Hunt[3] and Khandan Keyomarsi[1,5,6*]

Erratum

During the editorial process preceding the publication of this article an error was introduced in the heading of "Table 1 Univariate and multivariate analysis of elafin-positive cells in breast cancer patients." This error was only noticed after publication of the final version. Specifically, both data-containing columns are labeled "Elafin Negative." The data-containing column on the right should in fact be labeled "Elafin Positive (n = 482)." The corrected version can be found here (Table 1). Table 1 has also been updated in the original article to reflect the correct labeling of the columns.

Author details
[1]Department of Experimental Radiation Oncology, University of Texas at MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. [2]Department of Pathology, University of Texas at MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. [3]Department of Surgical Oncology, University of Texas at MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. [4]Baylor College of Medicine, Dan L. Duncan Cancer Center, 1 Baylor Plaza, Houston, Texas 77030, USA. [5]The University of Texas Graduate School of Biomedical Sciences, 6767 Bertner Ave, Houston, Texas 77030, USA. [6]Department of Experimental Oncology, UT, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 066, Houston, Texas 77030-4009, USA. [7]Department of Pathology, UC San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143-0511, USA.

References
1. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, et al. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Canc Res. 2014;16:3417.

* Correspondence: kkeyomar@mdanderson.org
[1]Department of Experimental Radiation Oncology, University of Texas at MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
[5]The University of Texas Graduate School of Biomedical Sciences, 6767 Bertner Ave, Houston, Texas 77030, USA
Full list of author information is available at the end of the article

Submit your next manuscript to BioMed Central and take full advantage of:

- **Convenient online submission**
- **Thorough peer review**
- **No space constraints or color figure charges**
- **Immediate publication on acceptance**
- **Inclusion in PubMed, CAS, Scopus and Google Scholar**
- **Research which is freely available for redistribution**

Submit your manuscript at
www.biomedcentral.com/submit

BioMed Central

BioMed Central

Caruso *et al. Breast Cancer Research* (2015) 17:87

Page 2 of 2

Table 1 Univariate and multivariate analysis of elafin-positive cells in breast cancer patients

A. Univariate analysis, breast cancer (n = 793)			
Factors	Elafin negative (n = 311)	Elafin positive (n = 482)	p-value
Age of diagnosis, year			0.02
Mean	55.5	53.5	
Median (range)	55 (26–86)	52 (25–87)	
Stage			<0.0001
I	120 (38.7)	115 (24.0)	
IIA	128 (41.3)	241 (50.2)	
IIB	62 (20.0)	124 (25.8)	
Unknown	1	2	
ER			<0.0001
Positive	266 (85.5)	280 (58.3)	
Negative	45 (14.5)	200 (41.7)	
Unknown	0	2	
PR			<0.0001
Positive	218 (70.1)	236 (49.2)	
Negative	93 (29.9)	244 (50.8)	
Unknown	0	2	
HER-2			0.013
Positive	42 (13.5)	98 (20.4)	
Negative	269 (86.5)	383 (79.6)	
Unknown	0	1	
Grade			<0.0001
I	41 (14.2)	31 (6.8)	
II	186 (64.6)	197 (43.5)	
III	61 (21.2)	225 (49.7)	
Unknown	23	29	
Tumor subtype			<0.0001
Luminal A	185 (61.9)	158 (33.1)	
Luminal B	45 (15.1)	94 (19.8)	
Her2 positive	42 (14.0)	98 (20.7)	
Triple negative	27 (9.0)	125 (26.4)	
Unknown	12	7	
Recurrence			<0.0001
No	250 (80.9)	298 (62.3)	
Yes	59 (19.1)	180 (37.7)	
Unknown	2	4	

Table 1 Univariate and multivariate analysis of elafin-positive cells in breast cancer patients *(Continued)*

B. Multivariate Cox proportional hazards analysis of clinicopathologic variables' influence on breast cancer RFS in whole cohort (n = 793)				
Factor	HR	Se	P	95% CI
Stage				
I	referent			
IIA	1.67	0.31	0.005	1.17-2.39
IIB	2.41	0.47	<0.0001	1.65-3.52
Age	0.98	0.01	<0.0001	0.97-0.99
Elafin Positive	1.94	0.3	<0.0001	1.44-2.62